Eisai Announces Japan MAH License from Nobelpharma for Antineoplastic Agent Gliadel 7.7mg Implant
November 25, 2013 at 05:57 AM EST
Eisai Co., Ltd. (OTC: ESALY ) announced today that it will receive the Marketing Authorization Holder (MAH) license for the antineoplastic agent Gliadel 7.7 mg Implant (carmustine, "Gliadel") in Japan from Nobelpharma Co., Ltd. (Headquarters: Tokyo, President & CEO: Jin Shiomura, "Nobelpharma"), effective December 2.In Japan, marketing authorization for
